Wang Yan, Zhou Yaojie, Zhou Kun, Li Jue, Che Guowei
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, P.R. China.
West China School of Medicine, Sichuan University, Chengdu, P.R. China.
Biomarkers. 2020 May;25(3):241-247. doi: 10.1080/1354750X.2020.1731763. Epub 2020 Feb 27.
In recent years, increasing studies found that pre-treatment red blood cell distribution width (RDW) could predict clinical outcomes in various cancers. However, the prognostic value of pre-treatment RDW in lung cancer was inconsistent. Therefore, we performed a meta-analysis to determine prognostic value of pre-treatment RDW in lung cancer. We performed a search in PubMed, The Cochrane Library, EMBASE (via OVID), Web of Science, CNKI, Wanfang, VIP, SinoMed databases, then we identified all records up to February 15, 2019. Outcomes of interest were overall survival (OS) and disease-free survival (DFS). Hazard ratios (HRs) and corresponding 95% confidence intervals (95% CIs) were calculated to assess the relevance of pre-treatment RDW to OS in lung cancer. We included ten articles in total. Pooled results revealed that elevated pre-treatment RDW was significantly associated with poor OS (HR = 1.55, 95% CI: 1.26-1.92, 0.001) and DFS (HR = 1.53, 95% Cl: 1.15-2.05; = 0.004) in lung cancer. Further subgroup analysis manifested that lung cancer patients with elevated pre-treatment RDW had worse prognosis. A higher value of pre-treatment RDW indicated worse survival of patients with lung cancer. RDW may serve as a reliable and economical marker for prediction of lung cancer prognosis.
近年来，越来越多的研究发现，治疗前红细胞分布宽度（RDW）可预测多种癌症的临床结局。然而，治疗前RDW在肺癌中的预后价值并不一致。因此，我们进行了一项荟萃分析，以确定治疗前RDW在肺癌中的预后价值。我们在PubMed、Cochrane图书馆、EMBASE（通过OVID）、Web of Science、中国知网、万方、维普、中国生物医学文献数据库中进行了检索，然后确定了截至2019年2月15日的所有记录。感兴趣的结局是总生存期（OS）和无病生存期（DFS）。计算风险比（HRs）和相应的95%置信区间（95% CIs），以评估治疗前RDW与肺癌OS的相关性。我们总共纳入了10篇文章。汇总结果显示，治疗前RDW升高与肺癌患者较差的OS（HR = 1.55，95% CI：1.26 - 1.92，P = 0.001）和DFS（HR = 1.53，95% Cl：1.15 - 2.05；P = 0.004）显著相关。进一步的亚组分析表明，治疗前RDW升高的肺癌患者预后较差。治疗前RDW值越高，肺癌患者的生存期越差。RDW可作为预测肺癌预后的可靠且经济的标志物。
